Overview

• SELLAS Q3 net loss narrows to $6.8 mln from $7.1 mln a year ago

• Company's cash position strengthened by $29.1 mln from warrant exercises in October

• Phase 3 REGAL trial of GPS and Phase 2 SLS009 program progressing as planned

Outlook

• SELLAS expects final analysis of Phase 3 REGAL trial by year-end 2025

• Company plans to start SLS009 trial in newly diagnosed AML patients in Q1 2026

Result Drivers

• R&D EXPENSES - Declined by $0.2 mln primarily due to lower clinical trial expenses and clinical and regulatory consulting costs

• G&A EXPENSES - Fell by $0.1 mln primarily attributable to a decrease in professional fees partially offset by an increase in personnel related expenses

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Sellas Life Sciences Group Inc is $7.00, about 78.4% above its November 11 closing price of $1.51

Press Release: ID:nGNX1qmSV1

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)